(CHSRI) UBS (CH) - MSCI - Ratings and Ratios
Swiss Stocks, Equity Funds, Investment Funds
Description: CHSRI UBS (CH) - MSCI
The UBS ETF (CH) - MSCI Switzerland IMI Socially Responsible (CHF) A-dis is an exchange-traded fund that tracks the Morningstar Switzerland TME NR CHF index, providing exposure to Swiss equities that meet certain socially responsible investing (SRI) criteria.
As a Switzerland Equity ETF, it is designed to capture the performance of the Swiss market, with a focus on companies that adhere to environmental, social, and governance (ESG) principles. The funds underlying index is likely constructed using a rules-based methodology that screens out companies involved in controversial activities or with poor ESG track records.
From a performance perspective, key metrics to monitor include the funds tracking error relative to its benchmark, as well as its returns relative to peers in the Switzerland Equity ETF category. Additional KPIs to consider include the funds expense ratio, trading liquidity, and the overall composition of its holdings, including sector and stock-level exposures.
Investors should also be aware of the funds investment universe and the specific SRI criteria used to construct the underlying index. This may include factors such as carbon footprint, labor practices, and board composition. By understanding these underlying drivers, investors can better assess the funds potential for long-term performance and alignment with their values.
Additional Sources for CHSRI ETF
CHSRI ETF Overview
Market Cap in USD | 344m |
Category | Switzerland Equity |
IPO / Inception | 2017-09-11 |
CHSRI ETF Ratings
Growth Rating | 41.1 |
Fundamental | - |
Dividend Rating | 44.7 |
Rel. Strength | -8.97 |
Analysts | - |
Fair Price Momentum | 17.33 CHF |
Fair Price DCF | - |
CHSRI Dividends
Dividend Yield 12m | 1.97% |
Yield on Cost 5y | 2.65% |
Annual Growth 5y | 8.77% |
Payout Consistency | 97.1% |
Payout Ratio | % |
CHSRI Growth Ratios
Growth Correlation 3m | 39.2% |
Growth Correlation 12m | 47.3% |
Growth Correlation 5y | 53.2% |
CAGR 5y | 6.30% |
CAGR/Max DD 5y | 0.23 |
Sharpe Ratio 12m | 0.61 |
Alpha | -6.76 |
Beta | 0.558 |
Volatility | 9.90% |
Current Volume | 7k |
Average Volume 20d | 8.3k |
Stop Loss | 17.9 (-3%) |
As of July 16, 2025, the stock is trading at CHF 18.46 with a total of 6,952 shares traded.
Over the past week, the price has changed by -0.03%, over one month by -0.74%, over three months by +7.37% and over the past year by +2.68%.
Partly, yes. Based on ValueRay´s Analyses, UBS (CH) - MSCI (SW:CHSRI) is currently (July 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 41.06 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CHSRI is around 17.33 CHF . This means that CHSRI is currently overvalued and has a potential downside of -6.12%.
UBS (CH) - MSCI has no consensus analysts rating.
According to our own proprietary Forecast Model, CHSRI UBS (CH) - MSCI will be worth about 19.4 in July 2026. The stock is currently trading at 18.46. This means that the stock has a potential upside of +5.04%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 19.4 | 5% |